Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark.

Annals of surgical oncology - 1 Oct 2018

Yang Shan, Axilbund Jennifer E, O'Leary Erin, Michalski Scott T, Evans Robbie, Lincoln Stephen E, Esplin Edward D, Nussbaum Robert L

Abstract excerpt

BACKGROUND: An estimated 5-10% of breast and ovarian cancers are due to hereditary causes such as hereditary breast and ovarian cancer (HBOC) syndrome. Medicare, the third-party payer that covers 44 million patients in the United States, has implemented a set of clinical criteria to determine coverage for the testing of the BRCA1 and BRCA2 genes. These criteria, developed to identify carriers of BRCA1/2 variants,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diagnostic Errors
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Genetic Testing

Share to Hereditary Breast and Ovarian Cancer Syndrome

Share to Patient Selection

Share to Treatment Outcome

Share to United States

Source

Identifiers

PMID: 29998407
DOI: 10.1245/s10434-018-6621-4

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark.PMID 29998407Read ↗

Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?Semantic proximity Read ↗

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.Semantic proximity Read ↗

Hereditary breast and ovarian cancer syndrome: considering the complexities.Semantic proximity Read ↗

Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.Semantic proximity Read ↗

BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.Semantic proximity Read ↗

BRCA1/2 Variants Identified Through Tumor Genomic Profiling: Assessing Genetic Counseling Outcomes.Semantic proximity Read ↗

Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare ProvidersSemantic proximity Read ↗

Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.Semantic proximity Read ↗

Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers.Semantic proximity Read ↗

Frequency of BRCA1 and BRCA2 mutations in a clinic-based series of breast and ovarian cancer families.Semantic proximity Read ↗

Occurrence of variants of unknown clinical significance in genetic testing for hereditary breast and ovarian cancer syndrome and Lynch syndrome: a literature review and analytical observational retrospective cohort study.Semantic proximity Read ↗

An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.